In an interview last year, two Epigenomics executives, Geert Walther Nygaard and Oliver Schacht, explained how their technology will improve the cancer outlook: ???DNA methylation biomarkers are present at very early stages of cancer development, and you can detect them from body fluids such as blood, plasma, and urine.